Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413509323> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2413509323 endingPage "42" @default.
- W2413509323 startingPage "36" @default.
- W2413509323 abstract "In the present study the results of the polycomponent vaccine B[symbol: see text]-4 use for the therapy of patients with bronchial asthma (BA) and latex allergy were generalized. The vaccine was introduced by the nasal-subcutaneous or nasal-oral administration simultaneously with the basic therapy. Te studies were conducted first on limited groups of patients, then in the course of the State Trial with the use of placebo control. Excellent and good effect lasting for 1 year and over was registered in 36 patients (66.7%) out of 54 BA patients receiving the vaccine by the intranasal-subcutaneous method. Immunotherapy produced no positive effect in 13 patients (24.1%). Out of 35 examined patients receiving the vaccine by the intranasal oral method, excellent and good effect was registered in 26 patients (74.2%). No effect was registered in 4 patients (11.4%). In the group of 28 patients receiving placebo simultaneously with the basic therapy positive dynamics in the course of the disease was observed only in 3 patients. Treatment with polycomponent vaccine B[symbol: see text]-4 led to a prolonged (to a year and more) decrease in the frequency and severity of exacerbations, contributed to the prolongation of remissions and to a decrease in the amount of administered medicinal preparations, especially systemic corticosteroids. Immunotherapy ensured the correction of the content of lymphocyte subpopulations with markers CD3, CD4, CD72 and a rise in the titers of antibodies to antigens contained in the preparation. The use of therapeutic polycomponent vaccine B[symbol: see text]-4 for the treatment of patients with latex allergy ensured the state of prolonged remission in this group of patients. On the basis of our investigations we believe that the use of the therapeutic polycomponent vaccine B[symbol: see text]-4 may be included into the basis therapy of allergic diseases." @default.
- W2413509323 created "2016-06-24" @default.
- W2413509323 creator A5038228086 @default.
- W2413509323 date "2003-03-13" @default.
- W2413509323 modified "2023-09-23" @default.
- W2413509323 title "[Multicomponent vaccine VP-4 in the therapy of allergic diseases]." @default.
- W2413509323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12630351" @default.
- W2413509323 hasPublicationYear "2003" @default.
- W2413509323 type Work @default.
- W2413509323 sameAs 2413509323 @default.
- W2413509323 citedByCount "2" @default.
- W2413509323 countsByYear W24135093232015 @default.
- W2413509323 countsByYear W24135093232020 @default.
- W2413509323 crossrefType "journal-article" @default.
- W2413509323 hasAuthorship W2413509323A5038228086 @default.
- W2413509323 hasConcept C126322002 @default.
- W2413509323 hasConcept C142724271 @default.
- W2413509323 hasConcept C159654299 @default.
- W2413509323 hasConcept C203014093 @default.
- W2413509323 hasConcept C204787440 @default.
- W2413509323 hasConcept C207480886 @default.
- W2413509323 hasConcept C27081682 @default.
- W2413509323 hasConcept C2776042228 @default.
- W2413509323 hasConcept C2776624504 @default.
- W2413509323 hasConcept C2777701055 @default.
- W2413509323 hasConcept C32611913 @default.
- W2413509323 hasConcept C71924100 @default.
- W2413509323 hasConcept C85663871 @default.
- W2413509323 hasConcept C8891405 @default.
- W2413509323 hasConceptScore W2413509323C126322002 @default.
- W2413509323 hasConceptScore W2413509323C142724271 @default.
- W2413509323 hasConceptScore W2413509323C159654299 @default.
- W2413509323 hasConceptScore W2413509323C203014093 @default.
- W2413509323 hasConceptScore W2413509323C204787440 @default.
- W2413509323 hasConceptScore W2413509323C207480886 @default.
- W2413509323 hasConceptScore W2413509323C27081682 @default.
- W2413509323 hasConceptScore W2413509323C2776042228 @default.
- W2413509323 hasConceptScore W2413509323C2776624504 @default.
- W2413509323 hasConceptScore W2413509323C2777701055 @default.
- W2413509323 hasConceptScore W2413509323C32611913 @default.
- W2413509323 hasConceptScore W2413509323C71924100 @default.
- W2413509323 hasConceptScore W2413509323C85663871 @default.
- W2413509323 hasConceptScore W2413509323C8891405 @default.
- W2413509323 hasIssue "1" @default.
- W2413509323 hasLocation W24135093231 @default.
- W2413509323 hasOpenAccess W2413509323 @default.
- W2413509323 hasPrimaryLocation W24135093231 @default.
- W2413509323 hasRelatedWork W1027324538 @default.
- W2413509323 hasRelatedWork W2003822157 @default.
- W2413509323 hasRelatedWork W2060290384 @default.
- W2413509323 hasRelatedWork W2066718029 @default.
- W2413509323 hasRelatedWork W2076382325 @default.
- W2413509323 hasRelatedWork W2076578054 @default.
- W2413509323 hasRelatedWork W2085861614 @default.
- W2413509323 hasRelatedWork W2162200176 @default.
- W2413509323 hasRelatedWork W2593689811 @default.
- W2413509323 hasRelatedWork W2600633258 @default.
- W2413509323 isParatext "false" @default.
- W2413509323 isRetracted "false" @default.
- W2413509323 magId "2413509323" @default.
- W2413509323 workType "article" @default.